APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Conjugate Vaccine (PCV)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumococcal Conjugate Vaccine (PCV) Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchPneumococcal Conjugate Vaccine (PCV) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Conjugate Vaccine (PCV) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Pneumococcal Conjugate Vaccine (PCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Conjugate Vaccine (PCV) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Conjugate Vaccine (PCV) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pneumococcal Conjugate Vaccine (PCV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumococcal Conjugate Vaccine (PCV) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumococcal Conjugate Vaccine (PCV) market include Sanofi, Merck, Pfizer, GSK, Zhifei Biologic, Walvax Biotechnology, Serum Institute of India and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pneumococcal Conjugate Vaccine (PCV) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Conjugate Vaccine (PCV) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Conjugate Vaccine (PCV) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pneumococcal Conjugate Vaccine (PCV) market.

Pneumococcal Conjugate Vaccine (PCV) Segment by Company

Sanofi

Merck

Pfizer

GSK

Zhifei Biologic

Walvax Biotechnology

Serum Institute of India

Royal (Wuxi) Bio-Pharmaceutical

Pneumococcal Conjugate Vaccine (PCV) Segment by Type

10-valent Vaccine

13-valent Vaccine

23-valent Vaccine

7-valent Vaccine

Pneumococcal Conjugate Vaccine (PCV) Segment by Application

Child

Adult

Pneumococcal Conjugate Vaccine (PCV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pneumococcal Conjugate Vaccine (PCV) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pneumococcal Conjugate Vaccine (PCV) key companies, revenue, market share, and recent developments.

3. To split the Pneumococcal Conjugate Vaccine (PCV) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pneumococcal Conjugate Vaccine (PCV) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumococcal Conjugate Vaccine (PCV) significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumococcal Conjugate Vaccine (PCV) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Conjugate Vaccine (PCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Conjugate Vaccine (PCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Conjugate Vaccine (PCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Conjugate Vaccine (PCV) industry.

Chapter 3: Detailed analysis of Pneumococcal Conjugate Vaccine (PCV) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pneumococcal Conjugate Vaccine (PCV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pneumococcal Conjugate Vaccine (PCV) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Conjugate Vaccine (PCV) Industry Trends Table 2. Pneumococcal Conjugate Vaccine (PCV) Industry Drivers Table 3. Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges Table 4. Pneumococcal Conjugate Vaccine (PCV) Industry Restraints Table 5. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Company (2021-2026) Table 7. Global Pneumococcal Conjugate Vaccine (PCV) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pneumococcal Conjugate Vaccine (PCV) Key Company Manufacturing Base & Headquarters Table 9. Global Pneumococcal Conjugate Vaccine (PCV) Company, Product Type & Application Table 10. Global Pneumococcal Conjugate Vaccine (PCV) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pneumococcal Conjugate Vaccine (PCV) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 10-valent Vaccine Table 15. Significant Companies of 13-valent Vaccine Table 16. Significant Companies of 23-valent Vaccine Table 17. Significant Companies of 7-valent Vaccine Table 18. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type (2021-2026) Table 22. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Child Table 24. Significant Companies of Adult Table 25. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application (2021-2026) Table 29. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application (2027-2032) Table 30. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Region (2021-2026) Table 33. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Region (2027-2032) Table 35. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Market Share by Country (2021-2026) Table 38. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Market Share by Country (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 44. Sanofi Recent Development Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 49. Merck Recent Development Table 50. Pfizer Company Information Table 51. Pfizer Business Overview Table 52. Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 54. Pfizer Recent Development Table 55. GSK Company Information Table 56. GSK Business Overview Table 57. GSK Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 59. GSK Recent Development Table 60. Zhifei Biologic Company Information Table 61. Zhifei Biologic Business Overview Table 62. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 64. Zhifei Biologic Recent Development Table 65. Walvax Biotechnology Company Information Table 66. Walvax Biotechnology Business Overview Table 67. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 69. Walvax Biotechnology Recent Development Table 70. Serum Institute of India Company Information Table 71. Serum Institute of India Business Overview Table 72. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 74. Serum Institute of India Recent Development Table 75. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 76. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 77. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 79. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Pneumococcal Conjugate Vaccine (PCV) Product Image Figure 2. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Conjugate Vaccine (PCV) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 10-valent Vaccine Image Figure 8. 13-valent Vaccine Image Figure 9. 23-valent Vaccine Image Figure 10. 7-valent Vaccine Image Figure 11. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type (2021-2032) Figure 14. Child Image Figure 15. Adult Image Figure 16. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application (2021-2032) Figure 19. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032) & (US$ Million) Figure 22. North America Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032) & (US$ Million) Figure 28. South America Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • 10-valent Vaccine
  • 13-valent Vaccine
  • 23-valent Vaccine
  • 7-valent Vaccine
Applications
  • Child
  • Adult
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • Zhifei Biologic
  • Walvax Biotechnology
  • Serum Institute of India
  • Royal (Wuxi) Bio-Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pneumococcal Conjugate Vaccine (PCV) Market Dynamics
  1. 2.1 Pneumococcal Conjugate Vaccine (PCV) Industry Trends
  2. 2.2 Pneumococcal Conjugate Vaccine (PCV) Industry Drivers
  3. 2.3 Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Conjugate Vaccine (PCV) Industry Restraints
3 Pneumococcal Conjugate Vaccine (PCV) Market by Company
  1. 3.1 Global Pneumococcal Conjugate Vaccine (PCV) Company Revenue Ranking in 2025
  2. 3.2 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Company (2021-2026)
  3. 3.3 Global Pneumococcal Conjugate Vaccine (PCV) Company Ranking (2024-2026)
  4. 3.4 Global Pneumococcal Conjugate Vaccine (PCV) Company Manufacturing Base and Headquarters
  5. 3.5 Global Pneumococcal Conjugate Vaccine (PCV) Company Product Type and Application
  6. 3.6 Global Pneumococcal Conjugate Vaccine (PCV) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pneumococcal Conjugate Vaccine (PCV) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pneumococcal Conjugate Vaccine (PCV) Market by Type
  1. 4.1 Pneumococcal Conjugate Vaccine (PCV) Type Introduction
  2. 4.1.1 10-valent Vaccine
  3. 4.1.2 13-valent Vaccine
  4. 4.1.3 23-valent Vaccine
  5. 4.1.4 7-valent Vaccine
  6. 4.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type
  7. 4.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Type (2021-2032)
  9. 4.2.3 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type (2021-2032)
5 Pneumococcal Conjugate Vaccine (PCV) Market by Application
  1. 5.1 Pneumococcal Conjugate Vaccine (PCV) Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Adult
  4. 5.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application
  5. 5.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Application (2021-2032)
  7. 5.2.3 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application (2021-2032)
6 Pneumococcal Conjugate Vaccine (PCV) Regional Value Analysis
  1. 6.1 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032)
  7. 6.3.2 North America Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032)
  10. 6.4.2 Europe Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032)
  16. 6.6.2 South America Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Country, 2025 VS 2032
7 Pneumococcal Conjugate Vaccine (PCV) Country-level Value Analysis
  1. 7.1 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pneumococcal Conjugate Vaccine (PCV) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pneumococcal Conjugate Vaccine (PCV) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Zhifei Biologic
  26. 8.5.1 Zhifei Biologic Company Information
  27. 8.5.2 Zhifei Biologic Business Overview
  28. 8.5.3 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  30. 8.5.5 Zhifei Biologic Recent Developments
  31. 8.6 Walvax Biotechnology
  32. 8.6.1 Walvax Biotechnology Company Information
  33. 8.6.2 Walvax Biotechnology Business Overview
  34. 8.6.3 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  36. 8.6.5 Walvax Biotechnology Recent Developments
  37. 8.7 Serum Institute of India
  38. 8.7.1 Serum Institute of India Company Information
  39. 8.7.2 Serum Institute of India Business Overview
  40. 8.7.3 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  42. 8.7.5 Serum Institute of India Recent Developments
  43. 8.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 8.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 8.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 8.8.3 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  48. 8.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst